Background: Narrowband-ultraviolet B (NB-UVB) is a promising, effective, and safe therapeutic option for atopic dermatitis (AD), but the treating courses frequently need an extended period since they might have a possible hazard for several side effects and cases of non-compliance.Objective: To discover the influence of platelet-rich plasma (PRP) injecting on the outcomes of short-term NB-UVB treatment for AD cases. Patients and methods:The present study includes 44 atopic dermatitis cases with general symmetric lesions. For every case, the left side of the body was treated with NB-UVB (control side) whereas the right side was treated with NB-UVB plus PRP intradermal injection, at 3-week interval for 3-months.Results: A statistically high significant reduction was found in the EASI score, IGA score in the combined side (PRP plus NB-UVB) in comparison with NB-UVB side. Conclusion:Intradermal PRP injecting in addition to NB-UVB can be considered as a simple, acceptable, and economical method for treating atopic dermatitis. It decreases the NB-UVB therapeutic period and is predictable to raise case compliance.Assessments through follow-up were proposed and undertaken to rate the efficacy of treatment.

Nada Elkady and colleagues describe their research-based work to design a steel transfer truss resistant to progressive collapse. The project won the Institution's Research into Practice case study competition in 2022.

Conclusions: Composite subgroups had higher shear bond strength than cyanoacrylate subgroups, but cyanoacrylate results were in the clinically acceptable range.

No abstract